Hence, at this time the main utility of targeted sequencing in WD/DD liposarcoma patients using commercially available panels such as FM would be to identify patients for clinical trials testing agents that target the MDM2 and/or the CDK4 pathway. Here, CDK4 is linked to Wilson disease.